Sales & Marketing News | pharmaphorum

News

Novo Nordisk sets aside $6bn to boost production capacity

Novo Nordisk is leaving nothing to chance when it comes to claiming a stake in the burgeoning market for diabetes and obesity therapies, announcing a plan to spend a whopp

News

Takeda gets okay in US for rare blood disorder drug

Patients in the US with ultra-rare blood clotting disorder congenital thrombotic thrombocytopenic purpura (cTTP) have an FDA-approved therapy for the first time, after Tak

News

First chikungunya vaccine approved by FDA

Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne dis

News

AstraZeneca builds in obesity with $2bn+ Eccogene deal

AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist

News

Lilly gets FDA okay for tirzepatide as obesity therapy

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a

News

Bayer to streamline management in cost-cutting drive

Bayer’s new chief executive Bill Anderson has launched a “re-design” of Bayer that will see layers of management stripped out by the end of next year, with “95% of the dec

Novo Nordisk sets aside $6bn to boost production capacity

Takeda gets okay in US for rare blood disorder drug

First chikungunya vaccine approved by FDA

AstraZeneca builds in obesity with $2bn+ Eccogene deal

Lilly gets FDA okay for tirzepatide as obesity therapy

Bayer to streamline management in cost-cutting drive

US judge says Novo Nordisk must face lawsuit over CagriSema

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks